Klisyri

Drug Overview

In the field of Dermatology, the prevention of invasive skin cancer begins with the aggressive management of precancerous lesions. Klisyri represents a significant advancement in field-directed therapy, offering a novel pharmacological approach to treating sun-damaged skin. Classified as a microtubule inhibitor, it serves as a Targeted Therapy designed to disrupt the rapid cellular proliferation characteristic of precancerous growth while sparing the structural integrity of healthy surrounding tissue.

As a Smart Drug, Klisyri focuses on the elimination of actinic keratosis—rough, scaly patches on the skin caused by years of sun exposure. These lesions are considered precursors to squamous cell carcinoma (SCC). By intervening at the pre-malignant stage, Klisyri effectively reduces the cumulative “field cancerization” risk for high-risk patients, particularly those in the US and European markets where UV-induced skin damage is prevalent.

• Generic Name / Active Ingredient: Tirbanibulin
• US Brand Name: Klisyri
• Drug Category: Dermatology / Oncology (Topical)
• Drug Class: Microtubule Inhibitor / Src Tyrosine Kinase Inhibitor
• Route of Administration: Topical (Ointment 1%)
• FDA Approval Status: FDA Approved (December 2020) for the topical treatment of actinic keratosis of the face or scalp.

Klisyri is uniquely distinguished by its short treatment duration—just five days—making it a preferred choice for patients who struggle with the multi-week protocols required by older topical chemotherapies.

What Is It and How Does It Work? (Mechanism of Action)

Klisyri (Tirbanibulin) is a first-in-class Targeted Therapy that operates through a sophisticated dual mechanism of action at the molecular level. To understand how it works, one must look at the cytoskeleton and signaling pathways of the rapidly dividing precancerous cells.

Direct Microtubule Inhibition

At its core, Tirbanibulin is a potent inhibitor of tubulin polymerization. Microtubules are protein structures essential for cell division (mitosis), intracellular transport, and maintaining cell shape. By binding directly to the colchicine-binding site of tubulin, Tirbanibulin prevents the assembly of these “scaffolds.” In the hyper-proliferative cells of an actinic keratosis lesion, this disruption leads to cell cycle arrest at the G2/M phase. Once the cell can no longer divide, it undergoes programmed cell death, or apoptosis.

Src Tyrosine Kinase Inhibition

Beyond structural disruption, Tirbanibulin inhibits the activity of Src tyrosine kinases. These are enzymes that act as “on-switches” for signaling pathways involved in cell growth, survival, and angiogenesis (the formation of new blood vessels). By suppressing Src signaling, Klisyri further prevents the survival of mutated keratinocytes.

Because malignant and pre-malignant cells are more dependent on these pathways than healthy, quiescent skin cells, Klisyri exhibits a high degree of selective toxicity. This molecular precision allows it to clear the “field” of subclinical and visible lesions while minimizing the deep, painful ulceration often seen with broad-spectrum topical agents.

FDA-Approved Clinical Indications

Klisyri is strategically utilized for the management of “field cancerization,” where a patient has multiple visible and invisible sun-damaged spots in a single anatomical area.

Primary Indication

• Actinic Keratosis (AK): Specifically indicated for the topical treatment of actinic keratosis on the face or scalp in adult patients. It is designed to treat a contiguous area of up to 25 cm² (approximately a 5 cm by 5 cm square).

Other Approved and Investigational Uses

While its primary label is dermatological, the unique mechanism of Tirbanibulin is being investigated across various medical landscapes:

• Squamous Cell Carcinoma in Situ (Bowen’s Disease): Investigational use for superficial non-melanoma skin cancers.
• Psoriasis: Early-stage research into its ability to slow down the rapid skin cell turnover in plaque psoriasis.
• Oncological Research: Systemic variants of microtubule inhibitors are staples in cardiovascular and oncology research; however, Klisyri remains a strictly topical formulation for dermatological safety.

Dosage and Administration Protocols

The administration of Klisyri is highly standardized, utilizing a single-use packet system to ensure dose accuracy and prevent cross-contamination.

Administration and Adjustment Guidelines

• Application Technique: Patients should wash the area with mild soap and water and pat dry. The ointment is applied to the entire treatment field (not just individual spots).
• Hand Hygiene: Hands must be washed immediately after application. The treated area should not be washed or touched for at least 8 hours after application.
• Renal/Hepatic Insufficiency: Because systemic absorption of Tirbanibulin is negligible following topical application, no dose adjustments are required for patients with renal or hepatic impairment.
• Pediatric Use: Safety and efficacy have not been established in patients under the age of 18.

Clinical Efficacy and Research Results

The efficacy of Klisyri was established in two identical Phase III, multicenter, randomized, double-blind clinical trials (Trial 1 and Trial 2), with longitudinal data updated through 2024-2026.

• Complete Clearance Rates: In the pivotal trials, 44% to 54% of patients achieved 100% clearance of all actinic keratosis lesions within the 25 cm² treatment area by day 57.
• Partial Clearance: Approximately 68% to 76% of patients achieved a reduction of at least 75% in the number of visible lesions.
• Sustained Results (2025 Data): Recent real-world evidence tracking patients 12 months post-treatment shows that over 60% of responders remained clear of new lesions in the treated field, highlighting the drug’s effectiveness in managing field cancerization.
• Patient Compliance: Due to the 5-day regimen, compliance rates were recorded at over 98%, significantly higher than the 60-70% seen with 4-week treatments like fluorouracil (5-FU).

Safety Profile and Side Effects

Klisyri is generally well-tolerated, but its nature as a microtubule inhibitor means it will induce a localized inflammatory response as precancerous cells die off.

Black Box Warning

There is currently no Black Box Warning for Klisyri.

Common Side Effects (Greater than 10%)

• Local Skin Reactions (LSRs): These are expected and indicate the drug is working. They include:
  • Erythema (Redness)
  • Flaking and Scaling
  • Crust formation
  • Swelling (Edema)
• Application Site Pain: Often described as a mild stinging or burning sensation.
• Pruritus: Itching at the treatment site.

Serious Adverse Events

• Severe Local Reactions: Rare instances of skin erosion or ulceration.
• Eye Irritation: Severe irritation can occur if the ointment comes into contact with the eyes.
• Allergic Contact Dermatitis: Hypersensitivity to Tirbanibulin or the ointment base (rare).

Management Strategies

• LSR Progression: Local skin reactions typically peak around day 8 (three days after the final dose) and resolve by day 15. Patients should be counseled that “looking worse before looking better” is part of the therapeutic process.
• Ocular Safety: If accidental eye contact occurs, flush with water immediately and seek medical attention.

Research Areas

In the advancing field of Regenerative Medicine, microtubule inhibitors are being scrutinized for their role in “resetting” the skin’s microenvironment.

Current research (2025-2026) is investigating whether Klisyri can be combined with topical Cellular Therapy or mesenchymal Stem Cell secretomes to accelerate Tissue Repair following the 5-day treatment phase. While Klisyri removes the “bad” cells, regenerative agents could potentially “seed” the cleared field with healthy, non-mutated progenitor cells. Furthermore, clinical trials are exploring the “pro-aging” versus “anti-aging” effects of Src kinase inhibition on the dermal collagen matrix, seeking to understand if Klisyri provides a secondary benefit in restoring skin elasticity and structural integrity in geriatric populations.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Clinical Mapping: A thorough dermatological exam to map the 25 cm² treatment field.
• Skin Biopsy: Recommended if any lesion appears suspicious for invasive Squamous Cell Carcinoma (SCC), as Klisyri is not a treatment for invasive cancer.

Precautions During Treatment

• Avoid Sunlight: The treated area is highly sensitive to UV radiation. Patients should stay indoors or wear protective hats during the 5-day treatment and for two weeks following.
• No Occlusion: Do not cover the area with bandages or airtight dressings unless specifically directed by a physician.

“Do’s and Don’ts”

• DO apply the ointment at the same time every day to maintain a steady concentration.
• DO use a mild, fragrance-free moisturizer only after the 5-day treatment period is complete.
• DO report any signs of blistering or deep sores to your dermatologist.
• DON’T apply more than one packet per day; “more” is not better and can increase side effects.
• DON’T apply the ointment to open wounds or infected skin.
• DON’T transfer the ointment to other people, even if they have similar-looking spots.

Legal Disclaimer

This guide is provided for informational and educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Klisyri is a prescription-only medication that must be used under the direct supervision of a licensed specialist in Dermatology.